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FROM several in vitro and in vivo studies involvement
of  somatostatin  (SMS)  in  intestinal  inflammation
emerge. Acute colitis induced in rats is attenuated by
the long-acting SMS analogue octreotide. We studied
the  potential  beneficial  effect  of  SMS  on  non-acute
experimental  colitis.  BALB/c  mice  received  either
saline, SMS-14 (36 or 120 m g daily) or octreotide (3 m g
daily)  subcutaneously delivered by implant osmotic
pumps.  A  non-acute  colitis  was  induced  by  admin-
istration  of  dextran  sodium  sulphate  (DSS)  10%  in
drinking  water  during  7  days.  DSS  evoked  a  mild,
superficial pancolitis, most characterized by mucosal
ulceration  and  submucosal  influx  of  neutrophils.
Neither  SMS-14  nor  octreotide  reduced  mucosal
inflammatory score or macroscopical disease activity,
although reduction of intestinal levels of interleukin-
1b (IL–1 b ), IL-6 and IL-10 during DSS was augmented
both  by  SMS  and  octreotide.  A  slight  increase  of
neutrophil  influx was  seen during  SMS  administra-
tion in animals not exposed  to DSS.  In conclusion,
SMS  or  its  long-acting  analogue  did  not  reduce
intestinal  inflammation  in  non-acute  DSS-induced
colitis.  According  to  the  cytokine  profile  observed,
SMS-14 and octreotide further diminished the reduc-
tion of  intestinal  macrophage  and  Th2  lymphocyte
activity.
Key  words:  intestinal  inflammation,  somatostatin,  neu-
ropeptide, experimental colitis, dextran sulphate
Introduction
Neuropeptides play key roles in intestinal inflamma-
tion.1 One of the most considerable inhibitory neu-
ropeptides  is  somatostatin  (SMS),  which  has  dose-
dependent  inhibitory  effects  on  lymphocyte
proliferation and cytokine production, immunoglobu-
lin synthesis and macrophage function.2 It stimulates
development and immunologic activity of intestinal
granulomas  in  murine  Schistosomiasis  mansoni
infection.3,4 Mucosal depletion of SMS is observed in
inflammatory  bowel  disease.5–8 In  contrast,  blood
SMS levels in active IBD are elevated, so a defensive
role  in  intestinal  mucosal  injury  is  suggested.9,10
Octreotide,  a  long-acting  SMS  analogue,  is  able  to
reduce epithelial damage in an animal model of acute
experimental  colitis.11 No  data  on  the  effects  of
somatostatin or its analogues on chronic colitis are
available.
When laboratory  animals are exposed to dextran
sulphate sodium (DSS) in their drinking water, a mild
colitis  develops. Although  one  of  the characteristic
events  evoked  by  DSS  is  an  enhanced  T -cell
response,12 colitis  is induced irrespective  the  pres-
ence  of  lymphocytes.13,14 DSS-induced colitis  is an
important,  reproducible  and  economic  model  of
intestinal inflammation, mimicking certain aspects of
inflammatory bowel disease.15 In the acute phase it is
characterized  by  a  predominantly  left-sided,  acute
colitis, which is not contiguous.16,17 Already 1 week
after starting  DSS exposure, a mild subacute colitis
has developed, which responds to several immune-
modulating  agents.18–20 Certainly  pro-inflammatory
neuropeptides  (substance  P ,  neuropeptide  Y)  are
involved in DSS-induced  colitis.21 The  relevance  of
inhibitory neuropeptides like SMS in this model has
not been studied before.
We  aimed to  determine  the  role  of  SMS  in DSS-
induced  subacute  intestinal  inflammation  in  mice,
focused on intestinal leukocyte infiltration and cyto-
kine content. Pro- as well as anti-inflammatory cyto-
kines were concerned in this study. Departing from
above  mentioned  immune  inhibitory  effects,  we
anticipated a beneficial effect of SMS administration
on intestinal mucosal damage.
Methods
Experimental protocol
All  experiments  were  approved  by  the  Laboratory
Animal Ethics Committee of the Erasmus University.
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randomly allocated to eight groups (A to H). All mice
received  subcutaneously  inserted  osmotic  pumps
(Alzet,  Germany)  which  were  placed in the  upper
region of the back under ether anaesthetic surgery.
Osmotic  pumps  were  filled  with  saline,  SMS-14  or
octreotide. Groups A and B received normal saline.
The pumps in groups C, D, E and F were filled with
SMS acetate, containing SMS-14 (Somatofalk®, Trame-
dico, Weesp, The  Netherlands). These  pumps  con-
tinuously released subcutaneous SMS-14 during 7 days
(groups C and D 36m g, and groups E and F 120m g
daily). Groups G and H received octreotide 3m g daily
(Sandostatine®, Novartis, Basle, Switzerland). Imme-
diately thereafter animals in groups B, D, F and H were
exposed to DSS 10% in their drinking water during 7
days. Control groups were allowed to drink normal
water. All animals had free access to drinking water
and normal food. Subsequent to an overnight fasting
animals were killed by cervical dislocation 7 days after
implantation  of  osmotic  pumps. All operations  and
sacrificing took place between 09.00 and 11.00h.
Macroscopy
Severity  of  inflammation  was  documented  macro-
scopically,  considering  changes  of  bodyweight  and
general appearance (hair, liveliness). Stools and rectal
bleeding, and colour, distension and serosal appear-
ance  of  the  colon  directly  after  opening  of  the
abdomen  were  scored.  A  maximum  macroscopic
score of  10 points was  allocated, according to  the
following:  as  adolescent  mice  gain  at  least  5%
bodyweight per week, change of bodyweight of more
than  5%  was  scored  0,  0–5%  gain  =  1,  loss  of
bodyweight = 2. Hair was normal (0) or dull (1); mice
were lively (0) or apathetic (1). Stools were normal
(0), semiliquid (1) or liquid (2). Rectal bleeding was
given 1 point. Colon colour was normal (0) or red (1);
distention  was  absent  (0)  or  remarkable  (1).  The
serosal aspect was normal (0) or thickened (1).
Intestinal specimens
Immediately  after  sacrificing,  the  colon  and  small
bowel were taken out. Faecal contents were carefully
removed. Fragments of terminal ileum, and proximal,
middle and distal colon were cut to a standardized
length  alongside  a  measuring  rod.  Specimens  for
histology were placed immediately in formaldehyde.
For cytokine analysis fragments were kept in Krebs’s
buffer after weighing.
Histological examination
Histological sections from ileum, and proximal, mid-
dle  and  distal  parts  of  the  colon  were  stained
(haematoxylin  and  eosin)  and  scored  to  extent  of
inflammation  (0  =none,  1=mild,  2=moderate,
3=severe),  damage  (0=none,  1=superficial,  2=invol-
vingm.mucosae,  3=transmural),  and  regeneration
(3=none,  2=focal,  1=multifocal,  0=complete).13
Assessments  were  made  by  a  blinded  committee.
Scores from proximal, middle and distal colon parts
were  added  to  obtain  a  total  histology  score  per
animal.
Cytokine analysis
Tissue  specimens  were  fragmented  during  10s  in
Krebs’s  buffer  (Ultra-Turrax,  Polyton,  Switzerland)
and  centrifuged  (10  000  3 g,  10min,  4°C).  The
supernatant was stored at –80°C for cytokine assay.
Levels  of  interleukin-1  beta  (IL-1b ),  IL-6,  IL-10  and
interferon  gamma  (IFNg )  were  measured  by  ELISA
kits  for  assay  of  mouse  cytokines  (Biosource,  Bel-
gium).  Levels  are  expressed as  cytokine  per  tissue
weight (pg/mg).
Analysis
Descriptive analysis was performed concerning mac-
roscopic changes. Cytokine values were expressed as
mean ± standard error. Results were analysed using a
Wilcoxon two-sided rank sum test for small samples
(macroscopy/microscopy) or an unpaired t-test (cyto-




All DSS-treated animals developed colitis and revealed
a significant higher macroscopy score than controls
(6.2 ± 1.2 vs. 0.4 ± 0.2, P < 0.01). Macroscopy scores
in groups C, E and G (‘non-inflamed’) did not differ
from controls (0.8 ± 0.6, 0.8 ± 0.4, and 0 ± 0, NS
compared  with  A).  Neither  SMS  nor  octreotide
significantly affected macroscopy scores in the colitis
groups D, F and H (4.8 ± 1.6, 5.8 ± 0.9 and 7.0 ± 1.4,
NS compared with B).
Histology
No inflammation was seen in the ileal specimens. A
mild pancolitis was induced by DSS. Mucosal infiltra-
tion  of  polymorphonuclear  neutrophils  (PMN)  was
the most remarkable finding. Histology scores from
proximal and distal colon parts in animals exposed to
DSS did not differ. Scores in groups B (7.2 ± 0.5), D
(8.8  ±  0.8),  F  (6.8  ±  0.6) and H  (8.6 ±  1.2)  were
significant higher than group A (3.0 ± 0.3, P £  0.05).
Scores from group E (3.6 ± 1.7) and G (4.2 ± 0.8)
were higher than controls, but these differences were
not  statistically  different.  In  group  C  inflammatory
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score  was  high  (5.2  ±  0.8),  merely  due  to  PMN
infiltration. Mucosal damage was not obviously pres-
ent in group C as the total microscopy score minus
the score for PMN infiltration was 1.6 ± 0.5 points for
group C, compared with 0.8 ± 0.2 points for controls
(P > 0.05).
Cytokines
IFNg was barely detectable in most samples (£ 0.4pg/
mg).  Statistical  analysis  was  not  possible,  due  to
abnormal distribution of data.
IL-1b levels in groups B, C, D, F , G and H (15.5 ±
3.3, 19.3 ± 3.5, 19.2 ± 7.3, 5.9 ± 1.7, 10.6 ± 1.8 and
10.1  ±  5.4pg/mg)  were  significantly  lower  than  in
group A (27.4 ± 5.3pg/mg, P £  0.05). Mucosal IL-1b
concentration in group E (27.5 ± 7.9pg/mg) was not
different from A (Fig. 1a). In F the IL-1b levels were
significantly lower than in B (P < 0.001).
IL-6 levels in groups B, D, F , G and H (21.3 ± 5.1,
21.4 ± 5.2, 14.1 ± 4.1, 27.4 ± 2.8 and 12.1 ± 5.9  pg/
mg) were lower than in group A (54.5 ± 11.2pg/mg,
P < 0.01, Fig. 1b). IL-6 levels in C (45.6 ± 5.5) and E
(51.7 ± 6.8pg/mg) did not differ from A (P>0.4). D, F ,
G  and  H  did  not  significantly  differ  from  B  (P =
0.2).
IL-10  concentration  (Fig.  1c)  in  group  B  (9.7  ±
3.8pg/mg) was lower than in A (20.9 ± 6.2pg/mg),
but statistical significance was not reached (P = 0.17).
IL-10 levels in D, F and H (6.7 ± 1.7, 6.3 ± 2.4 and 6.1
± 0.7pg/mg) were lower than in controls (P <0.05).
In groups C (16.2 ± 3.8pg/mg), E (22.8 ± 6.9pg/mg)
and  G  (14.9  ±  4.9pg/mg)  IL-10  levels  did  not
significantly differ from controls.
Discussion
In our study DSS induced a mild, superficial colitis,
both  left  and  right-sided,  rarely  involving  layers
beyond the muscularis mucosae. The most character-
izing finding was mucosal infiltration by neutrophils
(PMN). Neither SMS nor octreotide did attenuate DSS-
induced mucosal inflammation.  Low  dose SMS and
octreotide-treated  animals  that  were  exposed  to
normal  drinking  water  showed  a  marked  mucosal
infiltration  by  PMN,  without  mucosal  damage.  In
these  groups  mucosal  IL-1b content  was  reduced,
perhaps reflecting a negative feedback by increased
PMN influx. This increased PMN influx was limited to
the  colon,  as  all  ileal  specimens  were  normal. As
neutrophil migration into the intestinal mucosa is the
prominent  occurring  phenomenon  in  DSS-induced
colitis, the meaning of this infiltration without caus-
ing  mucosal  damage  is  unclear.  However,  in  vitro
leukocyte migration is stimulated by SMS,22,23 by an as
yet undefined mechanism.
Several beneficial effects of SMS or SMS analogues
on intestinal inflammation of various aetiologies have
been demonstrated.24–27 In an acute model of experi-
mental  colitis  (acetic  acid)  octreotide  in  high-dose
attenuated mucosal inflammation and local cytokine
Involvement of somatostation in intestinal inflammation
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FIG.  1.  Cytokine  levels  in  colon  mucosa  in  pg/mg  tissue
weight. A = saline; B = saline/DSS; C = SMS 36ug; D = SMS
36ug/DSS; E = SMS 120ug; F = SMS 120ug/DSS; G = OCT












)and eicosanoid production.11 A most distinct effect
was seen when octreotide was administered the day
before  induction  of  acute  colitis. As  no  follow-up
studies  on  rate  of  mucosal  regeneration  were  per-
formed, no data are known on the probable beneficial
effects of octreotide in the post-toxic period of acetic
acid. These  results  do  not  find  support  from  our
results, which might be due to the use of different
models  and  experimental  animals.  Acetic-acid-
induced colitis is an acute toxic model in which non-
specific inflammation prevails.15 DSS-induced murine
colitis  is  a  model  of  acute  as  well  as  non-acute
colitis.13,16,17 This model has been found suitable for
studying involvement of mediators of mucosal inflam-
mation  and  evaluation  of  anti-inflammatory  treat-
ment.18,20,28 DSS most likely acts as a direct mucosal
toxin,  as  inflammation  occurs  irrespective  of  the
presence of lymphocytes or other mucosal immuno-
cytes.13,14,29 However, in the non-acute DSS-induced
colitis intestinal macrophages, neutrophils and lym-
phocytes  are  affected.13,19,30 Corticosteroids, cyclo-
sporin  A  or  anti-neutrophil  serum  attenuate  DSS-
evoked inflammatory changes.18–20
In  chronic  DSS-induced  colitis  an  enhanced Th1
response  is  observed,  which  is  accompanied  by
increased  intestinal  IFNg content.31 However,  we
were  not  able  to  detect  IFN g in  our  intestinal
specimen,  perhaps  due  to  the  low  concentrations
observed after 7 days of DSS exposure.31 IL-4 levels
are  elevated  and IL-5  concentrations  drop after  14
days of DSS exposure,32 indicating differential effects
on Th2 activity. We found low mucosal IL-10 levels in
DSS-induced  colitis  compared  with  controls,  what
may  be  a  direct  or  indirect  effect  of  DSS  on Th2
lymphocytes. SMS and octreotide did not abolish this
effect, but even further amplified to reduction of IL-10
concentration. We observed a striking decrease of IL-
1b and IL-6, after 7 days of DSS administration. This
reduction  was  only  enhanced  by  SMS  120m g  and
octreotide. In the DSS model of experimental colitis a
reduced activity of mucosal macrophages as well as
Th2 lymphocytes may be expected. The reduction of
pro-inflammatory cytokines probably reflects a phase
of  mucosal  regeneration  in  this  stage  of  subacute
colitis after 1 week of DSS exposure. Probably, the
study  period  was  too  short  to  evaluate  expected
beneficial effects of SMS on the rate of post-exposure
healing. Moreover, adverse effects of SMS on intestinal
mucosal regeneration should be taken into account.33
The  dual  effect  of  different doses  SMS  may  reflect
different  local  mucosal  concentrations  and  subse-
quent  receptor  activation. This  effect  is  not  influ-
enced by the  short  half  time  of  this  instable  com-
pound,  considering  similar  results  obtained  by
octreotide.
In conclusion, in mice SMS or octreotide admin-
istered  subcutaneously  during  1  week  of  oral  DSS
exposure did not attenuate colon mucosal inflamma-
tion.  Low  levels  of  mucosal  IL-1b following  DSS
administration,  were  further  decreased during  high
doses SMS. During  administration  of SMS a marked
influx of PMN in colonic but not ileal mucosa was
observed, also in animals  not  receiving DSS. These
animals showed lower concentrations of mucosal IL-
1b than control animals. The meaning of this promo-
tive role of SMS on neutrophil migration still has to be
settled.  SMS  and  octreotide  amplified  DSS  induced
decline  of intestinal  levels  of  IL-1b ,  IL-6  and IL-10,
suggesting further inhibition of macrophages and Th2
lymphocytes.
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